ZINBRYTA® (daclizumab)

On March 2, 2018, Biogen and AbbVie announced the voluntary worldwide withdrawal of marketing authorisations for ZINBRYTA® (daclizumab) for relapsing multiple sclerosis.


Patients Consumer Medicine Information (CMI)
Healthcare Professionals Product Information (PI)

The cause of MS is not yet known. MS affects the brain and spinal cord. In MS, the body’s immune system reacts against its own myelin (the ‘insulation’ surrounding nerve fibres). In relapsing forms of MS, people have ‘exacerbations’ from time to time (eg. blurred vision, weakness in the legs or arms, or loss of control of bowel or bladder function). They are followed by periods of recovery. Recovery may be complete or incomplete. If it is incomplete there is ‘progression of disability’.